Raymond James Financial Inc. Takes Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Raymond James Financial Inc. bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 109,317 shares of the company's stock, valued at approximately $1,447,000.

Several other large investors have also made changes to their positions in TAK. Assetmark Inc. raised its holdings in Takeda Pharmaceutical by 6.4% during the 4th quarter. Assetmark Inc. now owns 86,167 shares of the company's stock worth $1,141,000 after purchasing an additional 5,185 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Takeda Pharmaceutical by 35.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 253,551 shares of the company's stock worth $3,357,000 after buying an additional 66,386 shares during the period. Schechter Investment Advisors LLC raised its stake in shares of Takeda Pharmaceutical by 2.5% during the fourth quarter. Schechter Investment Advisors LLC now owns 119,668 shares of the company's stock worth $1,584,000 after buying an additional 2,884 shares during the last quarter. Sage Rhino Capital LLC lifted its holdings in Takeda Pharmaceutical by 14.9% in the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after buying an additional 1,538 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in Takeda Pharmaceutical by 389.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 10,020 shares of the company's stock valued at $132,000 after acquiring an additional 7,972 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Trading Down 3.0 %

TAK traded down $0.45 during midday trading on Friday, reaching $14.74. 4,265,493 shares of the company were exchanged, compared to its average volume of 1,817,418. The stock has a market capitalization of $46.89 billion, a P/E ratio of 36.84, a PEG ratio of 0.24 and a beta of 0.39. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.37. The stock's 50-day simple moving average is $14.35 and its 200 day simple moving average is $13.92. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.